Skip to main content
SLSBio(Specialty Lab Solution Bio) Co., Ltd logo

SLSBio(Specialty Lab Solution Bio) Co., Ltd — Investor Relations & Filings

Ticker · 246250 ISIN · KR7246250005 KO Professional, scientific and technical activities
Open in API
Filings indexed 261 across all filing types
Latest filing 2024-03-08 AGM Information
Country KR South Korea
Listing KO 246250

About SLSBio(Specialty Lab Solution Bio) Co., Ltd

http://www.slabs.co.kr/

SLSBio (Specialty Lab Solution Bio) Co., Ltd. is a company specializing in laboratory solutions and support services for the pharmaceutical and biotechnology sectors. Its primary offerings include pharmaceutical quality control testing, clinical trial sample analysis, bioequivalence studies, drug stability testing, and new drug development support. In addition to its service portfolio, the company develops and manufactures diagnostic technologies, reagents, and other biological agents, supporting various stages of the drug development and commercialization lifecycle.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal regulatory filing titled '주주총회소집결의' (Resolution for Convening a General Meeting of Shareholders) and a subsequent correction ('정정신고'). It outlines the agenda for an upcoming Annual General Meeting (AGM), including items like financial statement approval, dividend declarations, and amendments to the articles of incorporation. Since this document serves as the official notice and resolution for the meeting rather than the presentation materials used during the meeting, it falls under the category of Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to vote on meeting agenda items.
2024-03-08 Korean
[기재정정]주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for SLS Bio. It includes the meeting agenda, details on proposed changes to the articles of incorporation, financial statements, and voting procedures. This document is a standard proxy statement/notice for an upcoming Annual General Meeting (AGM).
2024-03-08 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (Proxy Solicitation Statement). It contains information regarding the upcoming Annual General Meeting (AGM), including the agenda, voting procedures, and proxy solicitation details. While it includes financial statements, these are provided as part of the proxy materials to inform shareholders for the upcoming vote, rather than being the Annual Report (10-K) itself. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2024-03-08 Korean
[기재정정]현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KIND) regarding a 'Cash/In-kind Dividend Decision' (현금ㆍ현물배당 결정). It details the dividend amount per share, the dividend yield, and the approval process via the upcoming general meeting. Since this is a specific announcement regarding the declaration and details of a dividend payment, it falls under the 'Notice of Dividend Amount' category.
2024-02-29 Korean
배당락
Notice of Dividend Amount Classification · 100% confidence The document is a short notice regarding '배당락' (ex-dividend date) for the company SLS Bio. It provides the ex-dividend date, reference price, and the reason for the notice. This falls under the category of dividend-related announcements.
2024-02-27 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (SLS Bio) reporting a significant change (over 15%) in revenue or profit structure. This is a standard disclosure requirement for publicly traded companies in Korea (often referred to as a 'Fair Disclosure' or 'Significant Change' filing). Since it provides key financial highlights and reasons for the variance rather than being a full annual report or a simple announcement of a report's availability, it falls under the 'Earnings Release' category as it serves as the initial announcement of financial performance results. FY 2023
2024-02-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.